Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Securities code: 603567 Securities abbreviation: Zhenbaodao
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
2026 First Quarter Report
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder
The company's board of directors, directors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) guarantee that the financial information in the quarterly report is true, accurate and complete.
Are the first quarter financial statements audited?
□Yes √No
1. Main financial data
(1) Main accounting data and financial indicators
Unit: Yuan Currency: RMB
Items in this reporting period compared with the previous year. This reporting period. Same period last year. Changes in the same period.
Degree(%)
Operating income 181,561,015.33 468,943,569.26 -61.28 Total profit -226,539,821.76 86,771,521.34 -361.08 Net attributable to shareholders of listed companies
-179,949,070.12 75,295,443.26 -338.99 Profit
Deductions attributable to shareholders of listed companies
-182,530,612.07 72,577,143.11 -351.50Net profit except recurring gains and losses
1/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
cash flow from operating activities
63,795,363.60 -266,694,081.29 123.92 Net
Basic earnings per share (yuan/share) -0.1911 0.0800 -338.87 Diluted earnings per share (yuan/share) -0.1913 0.0800 -339.13 Weighted average return on equity, a decrease of 3.87 percentage points
-2.91 0.96 (%) points The end of this reporting period compared with the end of this reporting period The end of the previous year Increase or decrease at the end of the year
Range (%) Total assets 10,500,357,838.06 10,634,255,156.06 -1.26 All assets attributable to shareholders of listed companies
6,101,250,574.67 6,280,907,362.42 -2.86 Owners’ equity
(2) Non-recurring profit and loss items and amounts
√Applicable □Not applicable
Unit: Yuan Currency: RMB
Non-recurring gains and losses items Amount for the current period Description of gains and losses from disposal of non-current assets, including accrued asset deductions
-843,947.74
Offset portion of value provision
Government subsidies are included in the current profit and loss, but are not related to the company’s normal operations.
Closely related to business operations, in compliance with national policies and regulations, and in accordance with
4,066,572.05
Determined standards enjoy and have a lasting impact on the company's profits and losses
Except for government subsidies
Except for effective hedging related to the company’s normal business operations
In addition to business, non-financial enterprises hold financial assets and financial liabilities
-32,142.04
Gains and losses from changes in fair value of bonds and disposal financing
Profit and loss arising from assets and financial liabilities
The proportion of funds collected from non-financial enterprises included in the current profit and loss
fees
Gains and losses from entrusting others to invest or manage assets
Profit and loss from external entrusted loans
Due to force majeure factors, such as natural disasters
Loss of various assets
Reversal of impairment provision for accounts receivable that has been individually tested for impairment
The enterprise obtains investment from subsidiaries, associates and joint ventures
If the capital cost is less than when the investment is obtained, the invested unit shall enjoy
Gains from identifying the fair value of net assets
The balance sheet of subsidiaries resulting from business combinations under common control from the beginning to the end of the period
Net profit and loss for the current period on the date of merger
Gains and losses on non-monetary asset exchanges
2/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Debt restructuring gains and losses
An incident that occurs because the relevant business activities of the enterprise are no longer sustainable.
Sexual expenses, such as expenses for placement of employees, etc.
Due to adjustments in taxation, accounting and other laws and regulations, the current period's losses
one-time impact
The shares recognized in one go due to the cancellation or modification of the equity incentive plan
payment fee
For cash-settled share-based payment, on the vesting date
After that, losses arising from changes in the fair value of employee compensation payable
benefit
Investment properties that adopt the fair value model for subsequent measurement
Gains and losses arising from changes in fair value of real estate
Gains from transactions where the transaction price appears to be unfair
Contingencies unrelated to the company's normal business operations arise
Profit and loss
Custody fee income from entrusted operations
Other non-operating income and expenses other than the above items -110,612.47 Other profit and loss items that meet the definition of non-recurring gains and losses
Less: Impact on income tax 498,194.89 Impact on minority shareholders’ equity (after tax) 132.95
Total 2,581,541.95
If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable
(3) Changes in main accounting data and financial indicators and reasons
√Applicable □Not applicable
Project name Change ratio (%) Main reason Operating income -61.28 Mainly due to the fact that the sales scale did not meet expectations. Total profit -361.08
Attributable to shareholders of listed companies
-338.99
Net profit is mainly due to the decrease in gross profit level and the increase in impairment losses attributable to shareholders of listed companies. Net of non-recurring gains and losses -351.50
profit
cash flow from operating activities
123.92 is mainly due to the increase in sales collection. net amount
Basic earnings per share (yuan/share) -338.87 Mainly due to the decrease in net diluted earnings per share (yuan/share) -339.13 attributable to shareholders of listed companies.
3/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Share ordinary shareholders at the end of the reporting period Total number of preference shareholders whose voting rights were restored at the end of the reporting period (e.g.
30,322 0Total Yes)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Shareholding ratio of pledged, marked or frozen conditions Holding of sales restrictions
Name of shareholder Nature of shareholder Number of shares held
Example (%) Number of shares
Number of share certificates
Heilongjiang Chuangda Group Co., Ltd. Domestic non-state-owned Pledge 367,700,000
465,415,300 49.46 465,415,300
Company Legal person Freeze 270,000 Huzhou Saihan Equity Investment Contract Domestic non-state-owned
46,086,526 4.9 46,086,526 Private enterprise (limited partnership) Legal person
Bozhou Junze Fanglong Equity Investment Domestic non-state-owned
24,433,100 2.6 24,433,100 Unowned center (limited partnership) Legal person
Heilongjiang Chuangda Group Co., Ltd.
Company - 2023 Oriented
Non-public issuance by professional investors Others 20,725,323 2.2 20,725,323 Pledge 20,725,323 exchangeable corporate bonds
(First phase) Pledge account
Li Zhuo Domestic natural person 13,824,423 1.47 13,824,423 None China Merchants Bank Co., Ltd.
Company - Sino-European Alpha Hybrid Others 12,500,100 1.33 12,500,100 Intangible Securities Investment Fund
Shanghai Shengzhong Investment Management Co., Ltd.
Co., Ltd.-Shaoxing Binhai New
District biomedical industry equity Others 11,069,055 1.18 11,069,055 No investment fund partnership
(limited partnership)
Heilongjiang Chuangda Group Co., Ltd.
Company - 2023 Oriented
Non-public issuance by professional investors Others 8,746,056 0.93 8,746,056 Pledge 8,746,056 exchangeable corporate bonds
(Second phase) Pledge account
Hong Kong Securities Clearing Company Limited
Others 7,887,224 0.84 7,887,224 None
Qianhai Life Insurance Co., Ltd.
Ltd. - Participating insurance property Others 4,500,000 0.48 4,500,000 None
Shareholdings of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing) Name of shareholders Number of circulating shares without selling restrictions held Type and number of shares
4/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Share Type Quantity
Heilongjiang Chuangda Group Co., Ltd.
465,415,300 RMB ordinary shares 465,415,300 Company
Huzhou Saihan Equity Investment Co., Ltd.
46,086,526 RMB ordinary shares 46,086,526 partnerships (limited partnerships)
Bozhou Junze Fanglong Equity Investment
24,433,100 RMB ordinary shares 24,433,100 Capital Center (limited partnership)
Heilongjiang Chuangda Group Co., Ltd.
Company - 2023 Oriented
Non-public issuance by professional investors 20,725,323 RMB ordinary shares 20,725,323 exchangeable corporate bonds
(First phase) Pledge account
Li Zhuo 13,824,423 RMB ordinary shares 13,824,423 China Merchants Bank Co., Ltd.
Company - Sino-European Alpha Mixed 12,500,100 RMB ordinary shares 12,500,100 Securities Investment Fund
Shanghai Shengzhong Investment Management Co., Ltd.
Co., Ltd.-Shaoxing Binhai New
District biopharmaceutical industry equity 11,069,055 RMB ordinary shares 11,069,055 investment fund partnership
(limited partnership)
Heilongjiang Chuangda Group Co., Ltd.
Company - 2023 Oriented
Non-public issuance by professional investors of 8,746,056 RMB ordinary shares and 8,746,056 exchangeable corporate bonds
(Second phase) Pledge account
Hong Kong Securities Clearing Company Limited
7,887,224 RMB ordinary shares 7,887,224
Qianhai Life Insurance Co., Ltd.
Co., Ltd. - participating insurance property 4,500,000 RMB ordinary shares 4,500,000
Among the above-mentioned shareholders, Heilongjiang Chuangda Group Co., Ltd. and Bozhou Junze Fanglong Equity Investment Center (Co., Ltd.
There is no related relationship among the above-mentioned shareholders.
Heilongjiang Chuangda Group Co., Ltd. and Bozhou Junze Fanglong Equity Investment are related or acting in concert
Description of Capital Center (Limited Partnership) and Huzhou Saihan Equity Investment Partnership (Limited Partnership) and other shares
There is no related relationship or concerted action among shareholders, and the company does not know whether there is any relationship among the remaining shareholders.
There are related relationships and persons acting in concert.
Top 10 shareholders and top
10 unrestricted shareholders
Participate in margin trading and securities lending None
Refinancing business situation
Description (if any)
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
5/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
□Applicable √Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning □ Applicable √ Not applicable
3. Other reminders
Investors need to be reminded of other important information regarding the company’s operations during the reporting period.
□Applicable √Not applicable
4. Quarterly Financial Statements
(1) Types of audit opinions
□Applicable √Not applicable
(2) Financial statements
Consolidated Balance Sheet
March 31, 2026
Prepared by: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Item March 31, 2026 Current assets on December 31, 2025:
Monetary funds 54,126,352.30 78,911,075.80 Settlement reserves
Loan funds
Trading financial assets 406,367.22 438,509.26 Derivative financial assets
Notes receivable 1,713,157.98 6,945,699.03 Accounts receivable 2,404,859,613.70 2,553,600,785.27 Accounts receivable financing 252,074.12 1,785,507.60 Prepayments 320,825,430.18 217,849,248.37 Premiums receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 665,522,455.32 672,652,071.31 Including: interest receivable
Dividends receivable
Buy financial assets under resale agreements
Inventory 1,293,294,233.94 1,318,433,731.32 Including: data resources
Contract assets 7,178,815.05 7,178,815.05 Assets held for sale
6/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Non-current assets due within one year 4,466,028.20 4,739,595.53 Other current assets 285,604,474.77 286,171,583.36
Total current assets 5,038,249,002.78 5,148,706,621.90 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
long-term receivables
Long-term equity investment 717,424,229.11 719,405,782.37 Other equity instrument investment 569,978,489.88 591,200,000.00 Other non-current financial assets
Investment real estate 753,191,474.70 759,363,546.95 Fixed assets 1,225,769,090.65 1,255,886,802.63 Construction in progress 153,135,825.72 151,689,779.82 Productive biological assets
oil and gas assets
Right-of-use assets 9,517,873.32 11,126,092.82 Intangible assets 1,054,459,957.20 1,059,833,426.16 Including: data resources
Development expenditure 179,960,753.23 182,442,760.13 Including: data resources
Goodwill 14,823,926.83 14,823,926.83 Long-term deferred expenses 31,370,437.26 32,406,476.72 Deferred income tax assets 660,555,106.95 615,237,966.66 Other non-current assets 91,921,670.43 92,131,973.07 Total non-current assets 5,462,108,835.28 5,485,548,534.16
Total assets 10,500,357,838.06 10,634,255,156.06 Current liabilities:
Short-term borrowings 1,526,824,191.55 1,311,010,220.74 Borrowings from the central bank
borrowing funds
Trading financial liabilities
Derivative financial liabilities
Notes payable
Accounts payable 363,279,839.39 341,102,052.11 Advance receipts 10,806,881.40 10,642,258.60 Contract liabilities 84,850,683.04 127,557,477.78 Financial assets sold under repurchase agreements
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
Agent underwriting securities funds
Employee benefits payable 56,334,918.57 51,664,564.45
7/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Taxes payable 134,730,448.46 130,565,997.41 Other payables 346,811,430.13 339,273,398.01 Including: interest payable
Dividends payable
Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 1,109,429,684.77 1,754,079,075.30 Other current liabilities 6,175,804.34 19,623,563.24
Total current liabilities 3,639,243,881.65 4,085,518,607.64 Non-current liabilities:
insurance contract reserves
Long-term borrowings 506,000,000.00 47,000,000.00 Bonds payable
Among them: preferred shares
perpetual bond
Lease liabilities 5,335,644.85 6,203,297.80 Long-term payables
Long-term employee benefits payable
Estimated liabilities 57,299,202.11 57,299,202.11 Deferred income 132,676,375.20 137,452,362.53 Deferred income tax liabilities 20,477,958.91 20,809,953.71 Other non-current liabilities 808,373.40 808,373.30 Total non-current liabilities 722,597,554.47 269,573,189.45
Total liabilities 4,361,841,436.12 4,355,091,797.09 Owners’ equity (or shareholders’ equity):
Paid-in capital (or equity) 940,996,515.00 940,996,515.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 2,322,644,912.11 2,322,644,912.11 Less: treasury shares 13,885,131.37 13,885,131.37 Other comprehensive income
Special reserves 8,289,553.47 7,775,760.98 Surplus reserves 471,012,700.08 471,012,700.08 General risk reserves
Undistributed profits 2,372,192,025.38 2,552,362,605.62 Attributable to the owner’s equity of the parent company (or
6,101,250,574.67 6,280,907,362.42 shareholders’ equity) total
Minority shareholders’ equity 37,265,827.27 -1,744,003.45Owner’s equity (or shareholders’ equity)
6,138,516,401.94 6,279,163,358.97 Total
8/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Liabilities and owners' equity (or shares
10,500,357,838.06 10,634,255,156.06 East equity) Total
Person in charge of the company: Yan Jiujiang Person in charge of accounting work: Zhang Yanwei Person in charge of the accounting department: Zhang Yanwei
consolidated income statement
January-March 2026
Prepared by: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
- Total operating income 181,651,487.03 469,269,638.45 Including: operating income 181,561,015.33 468,943,569.26 Interest income 90,471.70 326,069.19 Premiums earned
Fee and commission income
- Total operating costs 299,548,775.47 283,091,788.40 Including: operating costs 180,987,299.23 118,332,086.10 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
Reinsurance cost
Taxes and surcharges 7,955,690.69 9,326,225.88 Sales expenses 14,107,466.69 48,229,446.08 Management expenses 57,204,688.14 68,363,736.89 Research and development expenses 8,637,372.96 3,333,409.32Financial expenses 30,656,257.76 35,506,884.13Including: Interest expenses 30,567,494.58 33,742,228.03
Interest income 13,842.14 733,939.73 plus: other income 4,066,572.05 5,365,914.45 Investment income (losses are listed with "-") -2,251,553.26 -6,262,138.90 Including: losses to associates and joint ventures
-2,251,553.26 -6,262,138.90Investment income
Financial assets measured at amortized cost
Derecognition of revenue
Exchange gains (losses are listed with "-")
Net exposure hedging gains (losses are marked with a "-"
Fill in the column)
Gains from changes in fair value (losses indicated by “-”
-32,142.04 -57,396.50 (fill in the numbers)
9/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Credit impairment losses (losses are filled in with "-"
-121,484,231.10 -92,215,588.01 columns)
Asset impairment losses (losses are filled in with "-"
12,013,381.24 -3,871,916.47 columns)
Asset disposal income (losses are filled in with "-"
-843,947.74 -11.33 columns)
- Operating profit (losses are listed with "-") -226,429,209.29 89,136,713.29 Plus: non-operating income 40,380.45 757,838.91 Less: non-operating expenses 150,992.92 3,123,030.86
4. Total profit (total loss is filled in with "-"
-226,539,821.76 86,771,521.34 columns)
Less: Income tax expense -45,600,582.48 12,753,578.19
- Net profit (net loss is listed with "-") -180,939,239.28 74,017,943.15
(1) Classification by business continuity
- Net profit from continuing operations (net loss is represented by “-”
-180,939,239.28 74,017,943.15 (please fill in the list)
- Net profit from discontinued operations (net loss is represented by “-”
(Fill in the number)
(2) Classification according to ownership ownership
- Net profit attributable to shareholders of the parent company (net
-179,949,070.12 75,295,443.26 Losses are listed with a “-” sign)
- Profit and loss of minority shareholders (net loss is marked with "-"
-990,169.16 -1,277,500.11 fill in the column)
6. Net amount of other comprehensive income after tax
(1) Other comprehensive assets attributable to the owners of the parent company
Earnings, net of taxes
- Other comprehensive income that cannot be reclassified into profit or loss
benefit
(1) Remeasurement of changes in defined benefit plan
(2) Other comprehensive items that cannot be transferred to profit or loss under the equity method
income
(3) Changes in fair value of other equity instrument investments
(4) Changes in the fair value of the company’s own credit risk
- Other comprehensive income to be reclassified into profit or loss
(1) Other comprehensive income that can be converted to profit or loss under the equity method
benefit
(2) Changes in fair value of other debt investments
(3) Financial assets are reclassified into other comprehensive income
amount of profit
(4) Credit impairment provisions for other debt investments
(5) Cash flow hedging reserve
(6) Translation differences of foreign currency financial statements
(7) Others
10/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
(2) Other comprehensive income attributable to minority shareholders
net profit after tax
- Total comprehensive income -180,939,239.28 74,017,943.15
(1) Comprehensive income attributable to owners of the parent company
-179,949,070.12 75,295,443.26 total profit
(2) Total comprehensive income attributable to minority shareholders
-990,169.16 -1,277,500.11 amount
8. Earnings per share:
(1) Basic earnings per share (yuan/share) -0.1911 0.0800
(2) Diluted earnings per share (yuan/share) -0.1913 0.0800 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.
Person in charge of the company: Yan Jiujiang Person in charge of accounting work: Zhang Yanwei Person in charge of the accounting department: Zhang Yanwei
Consolidated Cash Flow Statement
January-March 2026
Prepared by: Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
1. Cash flow generated from operating activities:
Cash received from sales of goods and provision of services 487,619,456.16 104,701,523.15 Net increase in customer deposits and interbank deposits
Um
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Um
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions 153,633.33 118,027.00 Net increase in borrowed funds
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
tax refund received
Other cash received related to operating activities 22,994,564.66 35,917,412.26
Subtotal of cash inflows from operating activities 510,767,654.15 140,736,962.41 Cash paid for purchasing goods and receiving services 376,122,010.78 220,102,871.78 Net increase in customer loans and advances
Net increase in deposits with central banks and inter-banks
Um
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
11/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 37,910,395.20 70,849,523.43 Various taxes paid 8,435,385.64 56,133,134.91 Other cash paid related to operating activities 24,504,498.93 60,345,513.58 Subtotal of cash outflows from operating activities 446,972,290.55 407,431,043.70 Net cash flow generated from operating activities
63,795,363.60 -266,694,081.29 amount
2. Cash flow generated from investing activities:
Cash received from recovery of investment 21,000,000.00
Cash received from investment income
Disposal of fixed assets, intangible assets and other
274,500.00
Net cash received from long-term assets
Received from disposal of subsidiaries and other business units
net cash
Other cash received related to investing activities
Subtotal of cash inflows from investing activities 21,274,500.00
Purchase and construction of fixed assets, intangible assets and other
11,669,102.14 29,606,742.65 Cash paid for long-term assets
Cash paid for investment 270,000.00 20,000,000.00 Net increase in pledged loans
Obtain payment from subsidiaries and other business units
net cash
Other cash payments related to investing activities
Subtotal of cash outflows from investing activities 11,939,102.14 49,606,742.65 Net cash flows from investing activities
9,335,397.86 -49,606,742.65 amount
3. Cash flow generated from financing activities:
Absorbing cash received from investments
Among them: subsidiaries absorb investment from minority shareholders
cash received
Cash received from borrowings 829,000,000.00 800,000,000.00 Cash received from other financing activities 631,199.54
Subtotal of cash inflows from financing activities 829,000,000.00 800,631,199.54 Cash paid to repay debts 893,500,000.00 722,000,000.00 Distribution of dividends, profits or interest payments
32,169,173.96 33,778,709.46 cash
Including: Payments made by subsidiaries to minority shareholders
dividends, profits
Cash payments related to other financing activities 348,641.53 95,700.00 Subtotal cash outflow from financing activities 926,017,815.49 755,874,409.46 Net cash flow generated from financing activities
-97,017,815.49 44,756,790.08 amount
12/13
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2026 First Quarter Report
4. Exchange rate changes on cash and cash equivalents
influence
- Net increase in cash and cash equivalents -23,887,054.03 -271,544,033.86
Add: Balance of cash and cash equivalents at the beginning of the period 76,895,401.15 1,050,313,244.04
- Balance of cash and cash equivalents at the end of the period 53,008,347.12 778,769,210.18 Person in charge of the company: Yan Jiujiang Person in charge of accounting work: Zhang Yanwei Person in charge of the accounting department: Zhang Yanwei
(3) The first implementation of new accounting standards or standard interpretations starting in 2026 will involve adjustments to the financial statements at the beginning of the year of first implementation.
□Applicable √Not applicable
Announcement hereby
Board of Directors of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. April 30, 2026
13/13